Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M. · 2022

Read Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. by Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9499862.txt.

Description

Bartsch and co-authors report the TUXEDO-1 phase 2 trial of trastuzumab deruxtecan in breast cancer that had spread to the brain. The drug is an antibody-drug conjugate with strong action outside the skull. Brain metastases are a heavy burden in HER2-positive disease. Active brain spread leaves few good options.

The open-label, single-arm trial enrolled 15 patients in its main count. All had prior trastuzumab and pertuzumab exposure. The drug was given at 5.4 mg per kg bodyweight every 3 weeks. Two patients had a complete intracranial response. Nine had a partial response and three had stable disease. The best overall intracranial response rate was 73.3%. That met the trial's preset primary goal. No new safety signals appeared, and quality of life held steady.

Catalog record

CREATORBartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, Bago-Horvath Z, Haslacher H, Widhalm G, Ilhan-Mutlu A, Minichsdorfer C, Fuereder T, Szekeres T, Oehler L, Gruenberger B, Singer CF, Weltermann A, Puhr R, Preusser M.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9499862

Browse the full library · About the Tower of Babel